MARKET

NRXPW

NRXPW

NRX Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.460
-0.005
-0.34%
Closed 16:00 01/26 EST
OPEN
1.580
PREV CLOSE
1.465
HIGH
1.580
LOW
1.460
VOLUME
13.40K
TURNOVER
--
52 WEEK HIGH
16.30
52 WEEK LOW
1.320
MARKET CAP
--
P/E (TTM)
-0.1836
1D
5D
1M
3M
1Y
5Y
BRIEF-Nrx Announces Publication Of Initial Findings Of Brilife® Vaccine-Produced Antibodies Against Omicron Variant
reuters.com · 1h ago
NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of neutralizing antibody agains...
PR Newswire · 2h ago
BRIEF-Nrx Receives Initial Report Of Patient Safety And Survival From Right To Try Use Of Zyesami (Aviptadil) During Omicron Surge
reuters.com · 1d ago
NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure. These pa...
PR Newswire · 1d ago
BRIEF-NRX Pharmaceuticals Announces Expansion Of Zyesami (Aviptadil) U.S. Expanded Access, Right To Try Programs For Patients With COVID-19
reuters.com · 01/18 12:09
NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments
ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Administration guide...
GlobeNewswire · 01/18 11:48
NRx Pharmaceuticals pursues Covid-19 vaccine as it continues work on treatment candidate
The Radnor company is also working on a Covid-19 therapy, which is currently part of an ongoing legal dispute with its one-time collaborator.
American City Business Journals · 01/14 20:12
BRIEF-NRx Responds To Relief’s Allegations Of January 14, 2022
reuters.com · 01/14 19:35
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRXPW. Analyze the recent business situations of NRX Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About NRXPW
NRX Pharmaceuticals, Inc., formerly Big Rock Partners Acquisition Corp., is a patient-focused, clinical stage pharmaceutical company. The Company is focused on developing NRX-101. NRX-101 is an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder and ZYESAMI (aviptadil), an intravenous and inhaled drug to treat respiratory failure in COVID-19. NRX-101 is designed to offer an oral, rapid-onset and sustained home-use therapy that can extend ketamine’s anti-suicidal benefit and reduce the side effects of ketamine. The Company combines D-cycloserine (DCS), a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NRX-101 is in Phase III of clinical testing.

Webull offers kinds of NRX Pharmaceuticals Inc stock information, including NASDAQ:NRXPW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRXPW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRXPW stock methods without spending real money on the virtual paper trading platform.